2020 Market Spotlight: Axial Spondyloarthritis (axSpA)
DUBLIN, April 3, 2020 /PRNewswire/ -- The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.
- DUBLIN, April 3, 2020 /PRNewswire/ -- The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.
- This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, and IL-17.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for axSpA, followed by AbbVie